Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BTTC with free AI briefings, catalyst countdowns, and dilution alerts.

BTTC · Black Titan Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.9M Cash, Jul 2026
7mo Cash Runway (est.)
+94% Share Count, 1 Year
Follow BTTC by email Get an email when BTTC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BTTC, unsubscribe in one click. Privacy

📣 What BTTC Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Silevertinib Non-Small Cell Lung Cancer Phase 1/2 · NCT05256290 Active not recruiting
Use autologous cSVF + MSCs (cryo) for… Autism Spectrum Disorder Phase 1/2 · NCT07546942 Enrolling by invitation
Tuxobertinib (BDTX-189) Solid Tumor Phase 1 · NCT04209465 Terminated
Liberase Enzyme (Roche) Pulmonary Alveolar Proteinosis Early Phase 1 · NCT04326036 Unknown

Also used in these trials (approved or third-party drugs, not BTTC's own candidates): Temozolomide, Azathioprine, Carfilzomib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BTTC reported $2.9M in cash and short-term investments (as of Jul 31, 2026) and used about $1.3M/quarter in operations, an estimated runway of 6.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 73 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BTTC files for a raise →

👥 Who Owns BTTC

Insiders 0% Other 5%+ holders 40.7% Institutions 0% Public and other holders 59.3%
HolderTypeShares% of sharesAs of
ARC Group Limited 5%+ holder (13G) 2,739,152 18.26% 2026-09-15
Danny Vincent Dass 5%+ holder (13D) 2,344,100 15.63% 2025-10-01
The Sire Group Ltd. 5%+ holder (13G) 1,019,313 6.80% 2025-11-11
Avraham Ben-Tzvi
Director
Insider 3,313 0.02% 2025-10-01

Share count 14,996,962 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BTTC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BTTC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.